Weill Cornell Medical College (MY, AL), New York, New York; and Department of Ophthalmology (A. Tandon, EJ, CG, A. Tooley, A. Tran, KJG, MD, CO), Weill Cornell Medical College, New York, New York.
J Neuroophthalmol. 2021 Dec 1;41(4):e631-e638. doi: 10.1097/WNO.0000000000001105.
Invasive fungal sinusitis carries high morbidity and mortality and often poses a diagnostic challenge. Orbital apex syndrome (OAS) is not an uncommon presentation in the setting of invasive fungal sinusitis. Delays in diagnosis and appropriate treatment can result in permanent visual dysfunction and, potentially, death. We present 2 cases of OAS secondary to invasive sinus aspergillosis, detailing the diagnostic process, treatment, and outcome for both patients. Subsequently, we present a review of the literature and combined analysis of our 2 patients plus 71 cases from previously published reports.
Literature review was performed to identify demographic, diagnostic, clinical, and treatment data of patients with OAS caused by Aspergillus species.
The review resulted in 52 included articles with 71 patients, plus our 2 reported patients, leading to a total of 73 subjects included in the analysis. The average age of patients at presentation was 59.9 years. A combination of visual disturbance and pain (headache and/or periocular pain) was the most common presentation reported (46 cases; 63%). Diabetes mellitus was reported in 15 cases (21%), with more than half specifically noted to have poorly controlled diabetes. After diabetes, the second most common cause of immunocompromise was chronic steroid use (n = 13; 18%). Empiric antifungal treatment was started in 10 patients (14%), while 25 patients (34%) were first treated with systemic steroids due to a concern for an inflammatory etiology. Time to diagnosis from initial presentation was on average 7.4 weeks (range of 0.3-40 weeks). Approximately 78% of the cases (57 of 73) had biopsies with histology that confirmed Aspergillus fungal morphology, and 30/73 (41%) had diagnostic fungal cultures. The majority of the cases received monotherapy with intravenous (IV) amphotericin B (36 patients; 49%) and IV voriconazole (19 patients; 26%), with a combination of the 2 or more antifungal agents being used in 11 patients (15%). Forty patients (55%) showed signs of clinical improvement with treatment, while 33 (45%) patients did not experience any improvement or continued to deteriorate, and 23 (32%) died in the course of their reported follow-up.
The present cases illustrate well the challenge in the diagnosis and treatment of OAS due to invasive sinus aspergillosis. Our review and analysis of 73 cases support the notion that a high index of suspicion leading to early biopsy with histology and fungal culture is paramount for diagnosis. Early empiric antifungal treatment and debridement can potentially reduce morbidity and mortality.
侵袭性真菌性鼻窦炎发病率和死亡率高,常构成诊断挑战。眶尖综合征(OAS)在侵袭性真菌性鼻窦炎中并不少见。诊断和适当治疗的延迟可能导致永久性视力障碍,并可能导致死亡。我们报告了 2 例由侵袭性鼻窦曲霉菌病引起的 OAS,详细介绍了这 2 例患者的诊断过程、治疗和结局。随后,我们对文献进行了综述,并对我们的 2 例患者以及之前发表的 71 例报告病例进行了综合分析。
对 OAS 由曲霉菌引起的患者的人口统计学、诊断、临床和治疗数据进行文献回顾。
文献回顾共纳入 52 篇文章,71 例患者,加上我们报告的 2 例患者,共纳入 73 例患者进行分析。患者就诊时的平均年龄为 59.9 岁。最常见的表现是视力障碍和疼痛(头痛和/或眶周疼痛)组合(46 例;63%)。15 例(21%)患者报告有糖尿病,其中一半以上患者有未得到良好控制的糖尿病。糖尿病之后,免疫抑制的第二大常见原因是慢性类固醇使用(n = 13;18%)。10 例(14%)患者开始经验性抗真菌治疗,而 25 例(34%)患者由于担心炎症病因而首先接受全身类固醇治疗。从初次就诊到确诊的平均时间为 7.4 周(范围 0.3-40 周)。约 78%的病例(73 例中有 57 例)有活检,组织学证实为曲霉菌真菌形态,30/73(41%)有诊断性真菌培养。大多数病例接受静脉注射(IV)两性霉素 B(36 例;49%)和 IV 伏立康唑(19 例;26%)单药治疗,11 例(15%)患者联合使用 2 种或更多种抗真菌药物。40 例(55%)患者经治疗后出现临床改善迹象,而 33 例(45%)患者无任何改善或持续恶化,23 例(32%)在报告的随访过程中死亡。
本病例很好地说明了诊断和治疗侵袭性鼻窦曲霉菌病引起的 OAS 的挑战。我们对 73 例病例的回顾和分析支持这样一种观点,即高度怀疑导致早期活检、组织学和真菌培养对于诊断至关重要。早期经验性抗真菌治疗和清创术可能会降低发病率和死亡率。